215 related articles for article (PubMed ID: 8993250)
21. In vitro evaluation of new surface coatings for extracorporeal circulation.
Baksaas ST; Videm V; Fosse E; Karlsen H; Pedersen T; Mollnes TE; Hagve TA; Svennevig JL
Perfusion; 1999 Jan; 14(1):11-9. PubMed ID: 10074642
[TBL] [Abstract][Full Text] [Related]
22. Limitation of thrombin generation, platelet activation, and inflammation by elimination of cardiotomy suction in patients undergoing coronary artery bypass grafting treated with heparin-bonded circuits.
Aldea GS; Soltow LO; Chandler WL; Triggs CM; Vocelka CR; Crockett GI; Shin YT; Curtis WE; Verrier ED
J Thorac Cardiovasc Surg; 2002 Apr; 123(4):742-55. PubMed ID: 11986603
[TBL] [Abstract][Full Text] [Related]
23. Heparin-coated circuits reduce the formation of TNF alpha during cardiopulmonary bypass.
Yamada H; Kudoh I; Hirose Y; Toyoshima M; Abe H; Kurahashi K
Acta Anaesthesiol Scand; 1996 Mar; 40(3):311-7. PubMed ID: 8721461
[TBL] [Abstract][Full Text] [Related]
24. Reduced granulocyte activation with a heparin-coated device in an in vitro model of cardiopulmonary bypass.
Videm V; Nilsson L; Venge P; Svennevig JL
Artif Organs; 1991 Apr; 15(2):90-5. PubMed ID: 1852153
[TBL] [Abstract][Full Text] [Related]
25. Clinical experience with heparin-coated cardiopulmonary bypass circuits.
Pradhan MJ; Fleming JS; Nkere UU; Arnold J; Wildlevuur CR; Taylor KM
Perfusion; 1991; 6(3):235-42. PubMed ID: 10149510
[TBL] [Abstract][Full Text] [Related]
26. Complement activation during extracorporeal circulation. In vitro comparison of Duraflo II heparin-coated and uncoated oxygenator circuits.
Svennevig JL; Geiran OR; Karlsen H; Pedersen T; Mollnes TE; Kongsgard U; Frøysaker T
J Thorac Cardiovasc Surg; 1993 Sep; 106(3):466-72. PubMed ID: 8361189
[TBL] [Abstract][Full Text] [Related]
27. Cell activation and thrombin generation in heparin bonded cardiopulmonary bypass circuits using a novel in vitro model.
Bannan S; Danby A; Cowan D; Ashraf S; Gesinde M; Martin P
Eur J Cardiothorac Surg; 1997 Aug; 12(2):268-75. PubMed ID: 9288518
[TBL] [Abstract][Full Text] [Related]
28. Differences in blood activation related to roller/centrifugal pumps and heparin-coated/uncoated surfaces in a cardiopulmonary bypass model circuit.
Moen O; Fosse E; Bråten J; Andersson C; Høgåsen K; Mollnes TE; Venge P; Kierulf P
Perfusion; 1996 Mar; 11(2):113-23. PubMed ID: 8740352
[TBL] [Abstract][Full Text] [Related]
29. Influence of Duraflo II heparin-treated extracorporeal circuits on the systemic inflammatory response in patients having coronary bypass.
Weerwind PW; Maessen JG; van Tits LJ; Stad RK; Fransen EJ; de Jong DS; Penn OC
J Thorac Cardiovasc Surg; 1995 Dec; 110(6):1633-41. PubMed ID: 8523873
[TBL] [Abstract][Full Text] [Related]
30. Heparin coating of extracorporeal circuits inhibits contact activation during cardiac operations.
te Velthuis H; Baufreton C; Jansen PG; Thijs CM; Hack CE; Sturk A; Wildevuur CR; Loisance DY
J Thorac Cardiovasc Surg; 1997 Jul; 114(1):117-22. PubMed ID: 9240301
[TBL] [Abstract][Full Text] [Related]
31. Cardiopulmonary bypass circuit treated with surface-modifying additives: a clinical evaluation of blood compatibility.
Gu YJ; Boonstra PW; Rijnsburger AA; Haan J; van Oeveren W
Ann Thorac Surg; 1998 May; 65(5):1342-7. PubMed ID: 9594864
[TBL] [Abstract][Full Text] [Related]
32. Heparin-coated cardiopulmonary bypass circuits in coronary bypass surgery.
Horimoto H; Kondo K; Asada K; Sasaki S
Artif Organs; 1996 Aug; 20(8):936-40. PubMed ID: 8853810
[TBL] [Abstract][Full Text] [Related]
33. Comparison of three oxygenator-coated and one total-circuit-coated extracorporeal devices.
Baksaas ST; Videm V; Pedersen T; Karlsen H; Mollnes TE; Brosstad F; Svennevig JL
Perfusion; 1999 Mar; 14(2):119-27. PubMed ID: 10338323
[TBL] [Abstract][Full Text] [Related]
34. Clinical study of platelet function and coagulation/fibrinolysis with Duraflo II heparin coated cardiopulmonary bypass equipment.
Nakajima T; Osawa S; Ogawa M; Sasaki T; Izumoto H; Yagi Y; Kawazoe K
ASAIO J; 1996; 42(4):301-5. PubMed ID: 8828788
[TBL] [Abstract][Full Text] [Related]
35. Biocompatibility of heparin-coated circuits used in cardiopulmonary bypass.
Pekna M; Borowiec J; Fagerhol MK; Venge P; Thelin S
Scand J Thorac Cardiovasc Surg; 1994; 28(1):5-11. PubMed ID: 7939508
[TBL] [Abstract][Full Text] [Related]
36. Effects of Duraflo II heparin-coated cardiopulmonary bypass circuits on the coagulation system, endothelial damage, and cytokine release in patients with cardiac operation employing aprotinin and steroids.
Inui K; Shimazaki Y; Watanabe T; Takahashi T; Minowa T; Takeda H; Yanagawa N; Sotoda Y
Artif Organs; 1999 Dec; 23(12):1107-12. PubMed ID: 10619929
[TBL] [Abstract][Full Text] [Related]
37. Deleterious effects of cardiopulmonary bypass on early graft function after single lung allotransplantation: evaluation of a heparin-coated bypass circuit.
Francalancia NA; Aeba R; Yousem SA; Griffith BP; Marrone GC
J Heart Lung Transplant; 1994; 13(3):498-507. PubMed ID: 8061027
[TBL] [Abstract][Full Text] [Related]
38. 'High dose' aprotinin and heparin-coated circuits: clinical efficacy and inflammatory response.
Parolari A; Alamanni F; Gherli T; Salis S; Spirito R; Foieni F; Rossi F; Bertera A; Oddono P; Biglioli P
Cardiovasc Surg; 1999 Jan; 7(1):117-27. PubMed ID: 10073771
[TBL] [Abstract][Full Text] [Related]
39. Coagulation, fibrinolysis, and cell activation in patients and shed mediastinal blood during coronary artery bypass grafting with a new heparin-coated surface.
Johnell M; Elgue G; Larsson R; Larsson A; Thelin S; Siegbahn A
J Thorac Cardiovasc Surg; 2002 Aug; 124(2):321-32. PubMed ID: 12167793
[TBL] [Abstract][Full Text] [Related]
40. Reduced complement activation and improved postoperative performance after cardiopulmonary bypass with heparin-coated circuits.
Jansen PG; te Velthuis H; Huybregts RA; Paulus R; Bulder ER; van der Spoel HI; Bezemer PD; Slaats EH; Eijsman L; Wildevuur CR
J Thorac Cardiovasc Surg; 1995 Sep; 110(3):829-34. PubMed ID: 7564452
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
